EFFECT OF PEGAPTANIB AND RANIBIZUMAB ON PLASMA AND VITREOUS HOMOCYSTEINE IN PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION.

Purpose: To investigate homocysteine (Hcy) concentration in the blood plasma and the vitreous in patients with exudative age-related macular degeneration receiving intravitreal anti-vascular endothelial growth factor therapy.

Methods: Plasma Hcy and vitreous Hcy levels were analyzed in 73 exudative age-related macular degeneration patients (50.7% received pegaptanib 0.

Influence of anti-VEGF about cardiovascular biomarkers in age related macular degeneration.

Systemic VEGF inhibition disrupts endothelial homeostasis and accelerates the atherogenesis, suggesting that these events contribute to the clinical cardiovascular adverse events of VEGF-inhibiting therapies. The objective of the current study was to analyze the effect of anti-VEGF therapy on cardiovascular risk factors in patients with exudative age related macular degeneration. A total of 73 patients with exudative age related macular degeneration (without previous anti-VEGF therapy) were treated with two anti-VEGF: Ranibizumab and Pegaptanib sodium.

Markers of cardiovascular risk in elderly patients with age-related macular degeneration.

Unlabelled: Age-related macular degeneration (AMD) is the leading cause of irreversible visual impairment and blindness among persons aged 60 years and older and many theories exist and feature mechanisms of oxidative stress, atherosclerotic-like changes, genetic predisposition, and inflammation in development of AMD. The aim of this study was to evaluate the association between markers of inflammation and cardiovascular risk with age-related macular degeneration.

Methods: Case-control study that includes 163 patients with wet AMD (age group of 55-82 years with the mean age of 71 years and 170 age-matched healthy controls in the age group of 55-78 years with the mean age of 71 years.

Liver lipocalin 2 expression in severely obese women with non alcoholic fatty liver disease.

Background: Lipocalin 2 (LCN2) has been related to obesity, insulin resistance and metabolic disturbance. However, its relation with non alcoholic fatty liver disease (NAFLD) has hardly been studied.

Methods: We examined LCN2 circulating levels and its protein and gene expression in liver from women with severe obesity and NAFLD.